BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34171446)

  • 1. Sialic acid conjugate-modified liposomal platform modulates immunosuppressive tumor microenvironment in multiple ways for improved immune checkpoint blockade therapy.
    Li C; Qiu Q; Gao X; Yan X; Fan C; Luo X; Liu X; Wang S; Lai X; Song Y; Deng Y
    J Control Release; 2021 Sep; 337():393-406. PubMed ID: 34171446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal Doxorubicin: the Sphingomyelin/Cholesterol System Significantly Enhances the Antitumor Efficacy of Doxorubicin.
    Meng X; Zhang H; Chen L; Wang M; Zhang K; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2023 Feb; 24(2):64. PubMed ID: 36759405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
    Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
    Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects.
    Li X; Zhu S; Yin P; Zhang S; Xu J; Zhang Q; Shi S; Zhang T
    Drug Deliv; 2021 Dec; 28(1):1849-1860. PubMed ID: 34515617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined immunochemotherapy achieving targeted co-delivery of chlorogenic acid and doxorubicin by sialic acid-modified liposomes enhances anti-cancer efficacy.
    Zhu S; Li X; Luo Z; Ding M; Shi S; Zhang T
    Drug Deliv Transl Res; 2024 Mar; 14(3):718-729. PubMed ID: 37679600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Ibrutinib to Tumor-Infiltrating T Cells with a Sialic Acid Conjugate-Modified Phospholipid Complex for Improved Tumor Immunotherapy.
    Li C; Fan C; Lu S; Qiu Q; Gao X; Yan X; Wang S; Zhao B; Liu X; Song Y; Deng Y
    Mol Pharm; 2023 Jan; 20(1):438-450. PubMed ID: 36382950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
    Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
    ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphatidylserine and/or Sialic Acid Modified Liposomes Increase Uptake by Tumor-associated Macrophages and Enhance the Anti-tumor Effect.
    Xu Z; Li J; Yan N; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2024 Jun; 25(5):125. PubMed ID: 38834759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-Eradication of Breast Cancer Cells and Cancer Stem Cells by Cross-Linked Multilamellar Liposomes Enhances Tumor Treatment.
    Kim YJ; Liu Y; Li S; Rohrs J; Zhang R; Zhang X; Wang P
    Mol Pharm; 2015 Aug; 12(8):2811-22. PubMed ID: 26098197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression.
    Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE
    J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity.
    Zhou S; Zhang T; Peng B; Luo X; Liu X; Hu L; Liu Y; Di D; Song Y; Deng Y
    Int J Pharm; 2017 May; 523(1):203-216. PubMed ID: 28336455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy.
    Kim J; Shim MK; Moon Y; Kim J; Cho H; Yun WS; Shim N; Seong JK; Lee Y; Lim DK; Kim K
    J Nanobiotechnology; 2024 Mar; 22(1):109. PubMed ID: 38481326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifunctional nanodrug performs sonodynamic therapy and inhibits TGF-β to boost immune response against colorectal cancer and liver metastasis.
    Huang S; Ding D; Lan T; He G; Ren J; Liang R; Zhong H; Chen G; Lu X; Shuai X; Wei B
    Acta Biomater; 2023 Jul; 164():538-552. PubMed ID: 37037269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Tri-Functional Liposome Re-Educates "Cold Tumor" and Abrogates Tumor Growth by Synergizing Autophagy Inhibition and PD-L1 Blockade.
    Zhou F; Li X; Xue X; Li S; Fan G; Cai Y; Chang Z; Qu J; Liu R
    Adv Healthc Mater; 2023 Apr; 12(11):e2202757. PubMed ID: 36652763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal oxaliplatin prodrugs loaded with metformin potentiate immunotherapy for colorectal cancer.
    Song L; Hao Y; Wang C; Han Y; Zhu Y; Feng L; Miao L; Liu Z
    J Control Release; 2022 Oct; 350():922-932. PubMed ID: 36108810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin-Loaded Platelet Decoys for Enhanced Chemoimmunotherapy Against Triple-Negative Breast Cancer in Mice Model.
    Dong H; Gao M; Lu L; Gui R; Fu Y
    Int J Nanomedicine; 2023; 18():3577-3593. PubMed ID: 37409026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages - A promising cancer immunotherapy.
    Tang X; Sui D; Liu M; Zhang H; Liu M; Wang S; Zhao D; Sun W; Liu M; Luo X; Lai X; Liu X; Deng Y; Song Y
    Int J Pharm; 2020 Nov; 590():119929. PubMed ID: 33010395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization design of sialic acid derivatives enhances the performance of liposomes for modulating immunosuppressive tumor microenvironments.
    Sui D; Liang K; Gui Y; Du Z; Xin D; Yu G; Zhai W; Liu X; Song Y; Deng Y
    Life Sci; 2022 Dec; 310():121081. PubMed ID: 36273630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin-isoniazid conjugate regulates immune response and tumor microenvironment to enhance cancer therapy.
    Jin C; Li J; Yang X; Zhou S; Li C; Yu J; Wang Z; Wang D; He Z; Jiang Y; Wang Y
    Int J Pharm; 2023 Jan; 631():122509. PubMed ID: 36549403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Application of Tumor-Associated Macrophages as Immunotherapy Targets: Sialic Acid-Modified EPI-Loaded Liposomes Inhibit Breast Cancer Metastasis.
    Meng X; Wang M; Zhang K; Sui D; Chen M; Xu Z; Guo T; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2022 Oct; 23(8):285. PubMed ID: 36258152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.